Cardax, Inc.
CDXI
Rank in Stocks
#35293
Cardax, Inc. is a biopharmaceutical enterprise focused on both creating and... Cardax, Inc. is a biopharmaceutical enterprise focused on both creating and marketing nutritional supplements for maintaining inflammatory well-being, as well as developing pharmaceutical treatments for chronic ailments rooted in inflammation and oxidative stress. Its product portfolio includes ZanthoSyn, an advanced supplement for inflammation, health, and longevity that delivers astaxanthin with superior absorption and purity. This product is primarily distributed through online sales and wholesale channels. The company is also progressing two pharmaceutical candidates: CDX-101, an astaxanthin-derived drug candidate intended to address cardiovascular inflammation and dyslipidemia, with a primary focus on severe hypertriglyceridemia; and CDX-301, a zeaxanthin-based pharmaceutical currently under development for macular degeneration. Cardax, Inc. maintains its headquarters in Honolulu, Hawaii.
Share Price
$0.0001
Last synced: 2026-11-06
Market Cap
$80.00
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Cardax, Inc. (CDXI)
Category
Healthcare
EPS for Cardax, Inc. (CDXI)
EPS as of March 2021 TTM: $-10.03
According to Cardax, Inc.'s latest financial reports, its current EPS (TTM) is $-10.03. At the end of 2020 the company had an EPS of $-6.79, an increase over its 2019 EPS of $-8.40.
EPS history for Cardax, Inc. from 2012 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-10.03 | 47.72% |
| 2020 | $-6.79 | -19.17% |
| 2019 | $-8.40 | 32.91% |
| 2018 | $-6.32 | 59.19% |
| 2017 | $-3.97 | -15.17% |
| 2016 | $-4.68 | -63.24% |
| 2015 | $-12.73 | -77.45% |
| 2014 | $-56.44 | 20,057.14% |
| 2013 | $-0.28 | 536.36% |
| 2012 | $-0.04 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -256.13% |
US
|
|
| $-7.07 | -29.51% |
US
|
|
| $-5.29 | -47.26% |
AU
|
|
| $12.88 | -228.42% |
BE
|
|
| $21.56 | -314.96% |
NL
|
Questions about Cardax, Inc.'s earnings per share (EPS)
What is Cardax, Inc.'s earnings per share (EPS)?
Cardax, Inc.'s earnings per share (EPS) over the last twelve months is $-10.03, as of Mar 2021.
What was Cardax, Inc.'s earnings per share (EPS) in 2020?
In 2020, Cardax, Inc.'s earnings per share (EPS) was $-6.79, compared with $-8.40 in 2019.
How has Cardax, Inc.'s earnings per share (EPS) changed since 2015?
From 2015 to 2020, Cardax, Inc.'s earnings per share (EPS) was highest in 2017 ($-3.97) and lowest in 2015 ($-12.73).
How does Cardax, Inc.'s earnings per share (EPS) compare with similar companies?
Cardax, Inc.'s earnings per share (EPS) ($-10.03) is lower than that of all 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.